NeuroPace, Inc. (NPCE)

NGM – Цена в реальном времени. Валюта: USD

15.80

+0.13 (0.83%)

При закрытии: May 12, 2026, 4:00 PM EDT

15.38

-0.42 (-2.66%)

До открытия: May 13, 2026, 4:01 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

NeuroPace, Inc. (NPCE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

NeuroPace, Inc. (NPCE)

NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript

NeuroPace Q1 Earnings Call Highlights

NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates

NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NeuroPace (NPCE) Moves 6.3% Higher: Will This Strength Last?

NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026

Видео

No Data

Пресс-релизы

NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026

NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

Search stocks

NeuroPace, Inc. (NPCE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

NeuroPace, Inc. (NPCE)

NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript

NeuroPace Q1 Earnings Call Highlights

NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates

NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NeuroPace (NPCE) Moves 6.3% Higher: Will This Strength Last?

NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026

Видео

No Data

Пресс-релизы

NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026

NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook